356 related articles for article (PubMed ID: 27870730)
21. "Second hit" in sebaceous tumors from Muir-Torre patients with germline mutations in MSH2: allele loss is not the preferred mode of inactivation.
Kruse R; Rütten A; Hosseiny-Malayeri HR; Bisceglia M; Friedl W; Propping P; Ruzicka T; Mangold E
J Invest Dermatol; 2001 Mar; 116(3):463-5. PubMed ID: 11231323
[TBL] [Abstract][Full Text] [Related]
22. Identification of Muir-Torre syndrome among patients with sebaceous tumors and keratoacanthomas: role of clinical features, microsatellite instability, and immunohistochemistry.
Ponti G; Losi L; Di Gregorio C; Roncucci L; Pedroni M; Scarselli A; Benatti P; Seidenari S; Pellacani G; Lembo L; Rossi G; Marino M; Lucci-Cordisco E; Ponz de Leon M
Cancer; 2005 Mar; 103(5):1018-25. PubMed ID: 15662714
[TBL] [Abstract][Full Text] [Related]
23. Considerations on the performance of immunohistochemistry for mismatch repair gene proteins in cases of sebaceous neoplasms and keratoacanthomas with reference to Muir-Torre syndrome.
Fernandez-Flores A
Am J Dermatopathol; 2012 Jun; 34(4):416-22. PubMed ID: 22123265
[TBL] [Abstract][Full Text] [Related]
24. Muir-Torre syndrome: sebaceous carcinoma concurrent with colon cancer in a kidney transplant recipient; a case report.
Tomonari M; Shimada M; Nakada Y; Yamamoto I; Itoh M; Koike Y; Kobayashi A; Miki J; Yamada H; Kimura T; Saito S; Sugano K; Sekine S; Yamamoto H; Asahina A; Yokoo T
BMC Nephrol; 2019 Oct; 20(1):394. PubMed ID: 31664942
[TBL] [Abstract][Full Text] [Related]
25. An Intrapatient Concordance Study of Mismatch Repair Protein Immunohistochemical Staining Patterns in Patients With Muir-Torre Syndrome.
Nguyen CV; Gaddis KJ; Stephens MR; Seykora JT; Chu EY
JAMA Dermatol; 2020 Jun; 156(6):676-680. PubMed ID: 32267475
[TBL] [Abstract][Full Text] [Related]
26. Muir-Torre syndrome or phenocopy? The value of the immunohistochemical expression of mismatch repair proteins in sebaceous tumors of immunocompromised patients.
Ponti G; Pellacani G; Ruini C; Percesepe A; Longo C; Mandel VD; Crucianelli F; Gorelli G; Tomasi A
Fam Cancer; 2014 Dec; 13(4):553-61. PubMed ID: 24969397
[TBL] [Abstract][Full Text] [Related]
27. [Muir-Torre syndrome: rare association with duodenal carcinoma].
Bacha D; Deschamps L; Sauvanet A; Couvelard A
Ann Pathol; 2009 Dec; 29(6):495-8. PubMed ID: 20005439
[TBL] [Abstract][Full Text] [Related]
28. The Muir-Torre syndrome: a disease of sebaceous and colonic neoplasms.
Schwartz RA; Goldberg DJ; Mahmood F; DeJager RL; Lambert WC; Najem AZ; Cohen PJ
Dermatologica; 1989; 178(1):23-8. PubMed ID: 2917677
[TBL] [Abstract][Full Text] [Related]
29. Tumor mutational signatures in sebaceous skin lesions from individuals with Lynch syndrome.
Georgeson P; Walsh MD; Clendenning M; Daneshvar S; Pope BJ; Mahmood K; Joo JE; Jayasekara H; Jenkins MA; Winship IM; Buchanan DD
Mol Genet Genomic Med; 2019 Jul; 7(7):e00781. PubMed ID: 31162827
[TBL] [Abstract][Full Text] [Related]
30. Parotid Sebaceous Carcinoma in Patient with Muir Torre Syndrome, Caused by MSH2 Mutation.
Neelakantan IV; Di Palma S; Smith CE; McCoombe A
Head Neck Pathol; 2016 Sep; 10(3):354-61. PubMed ID: 26577210
[TBL] [Abstract][Full Text] [Related]
31. Microsatellite and genetic instability in patients with Muir-Torre syndrome.
Lorente-Lavirgen AI; Morillo-Andújar M; Zulueta-Dorado T; Conejo-Mir J
Actas Dermosifiliogr; 2013 Sep; 104(7):643-4. PubMed ID: 23891449
[No Abstract] [Full Text] [Related]
32. Muir-Torre syndrome: a case of unusual coexisting genetic mutations.
Cino D; Drumm C; Sheahan K; D'Arcy C; Nolan N; Hoti E; Winter D; O'Duffy F; Dolan R; Moriarty B
Clin Exp Dermatol; 2022 Mar; 47(3):602-604. PubMed ID: 34762321
[TBL] [Abstract][Full Text] [Related]
33. All patients with sebaceous gland neoplasms should be screened for Muir-Torre syndrome.
Ingram JR; Griffiths AP; Roberts DL
Clin Exp Dermatol; 2009 Mar; 34(2):264-6. PubMed ID: 19187311
[No Abstract] [Full Text] [Related]
34. Clinical and Molecular Features of Skin Malignancies in Muir-Torre Syndrome.
Simic D; Dummer R; Freiberger SN; Ramelyte E; Barysch MJ
Genes (Basel); 2021 May; 12(5):. PubMed ID: 34065301
[TBL] [Abstract][Full Text] [Related]
35. Sebaceous skin lesions as clues to hereditary non-polyposis colorectal cancer.
Lynch HT; Fusaro RM; Lynch PM
J Invest Dermatol; 2006 Oct; 126(10):2158-9. PubMed ID: 16983324
[TBL] [Abstract][Full Text] [Related]
36. BRAF/KRAS gene sequencing of sebaceous neoplasms after mismatch repair protein analysis.
Cornejo KM; Hutchinson L; Deng A; Tomaszewicz K; Welch M; Lyle S; Dresser K; Cosar EF
Hum Pathol; 2014 Jun; 45(6):1213-20. PubMed ID: 24767862
[TBL] [Abstract][Full Text] [Related]
37. Fordyce granules and hyperplastic mucosal sebaceous glands as distinctive stigmata in Muir-Torre syndrome patients: characterization with reflectance confocal microscopy.
Ponti G; Meschieri A; Pollio A; Ruini C; Manfredini M; Longo C; Mandel VD; Ciardo S; Tomasi A; Giannetti L; Pellacani G
J Oral Pathol Med; 2015 Aug; 44(7):552-7. PubMed ID: 25213213
[TBL] [Abstract][Full Text] [Related]
38. The natural history of a combined defect in MSH6 and MUTYH in a HNPCC family.
van Puijenbroek M; Nielsen M; Reinards TH; Weiss MM; Wagner A; Hendriks YM; Vasen HF; Tops CM; Wijnen J; van Wezel T; Hes FJ; Morreau H
Fam Cancer; 2007; 6(1):43-51. PubMed ID: 17039270
[TBL] [Abstract][Full Text] [Related]
39. Immunohistochemistry screening of sebaceous lesions for Muir-Torre syndrome in a 26-year period in a Mexican population.
Archer-Dubon C; Alvarez-Zavala B; Reyes E; Orozco-Topete R
Dermatol Online J; 2008 Dec; 14(12):1. PubMed ID: 19265614
[TBL] [Abstract][Full Text] [Related]
40. Muir-Torre syndrome caused by exonic deletion of MLH1 due to homologous recombination.
Shiki M; Hida T; Sugano K; Kaneko R; Kamiya T; Sakurai A; Yamashita T
Eur J Dermatol; 2017 Feb; 27(1):54-58. PubMed ID: 28120777
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
